Influence of Bacterial Endotoxin on Mucosal Immune Response to Phosphorylcholine

Sapta Adisuka Mulyatno; Kosuke Kataoka; Makoto Fukui; Tselmeg Baatarjav Rita Cristina Orihuela Campos; Hiro-O Ito

doi:10.22146/theindjdentres.65711

Influence of Bacterial Endotoxin on Mucosal Immune Response to Phosphorylcholine

https://doi.org/10.22146/theindjdentres.65711

Sapta Adisuka Mulyatno⁽¹⁾, Kosuke Kataoka⁽²⁾, Makoto Fukui⁽³⁾, Tselmeg Baatarjav Rita Cristina Orihuela Campos⁽⁴⁾, Hiro-O Ito^(5*)

(1) Department of Preventive Dentistry, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima
(2) Department of Preventive Dentistry, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima
(3) Department of Preventive Dentistry, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima
(4) Department of Preventive Dentistry, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima
(5) Department of Preventive Dentistry, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima
(*) Corresponding Author

Abstract

Bacterial lipopolysaccharide (LPS), a component of the outer membrane of gram-negative bacteria
that initiates inflammation by activation innate immune responses through Toll-like receptor 4
(TLR4). However, the influence of LPS on the mucosal immune reactions remains to be addressed.
This study was examined the effect of LPS in nasal vaccination model. BALB/c and C57BL/6 mice
were nasally immunized with keyhole limpet hemocyanin (KLH) conjugated with hapten phosphorylcholine (PC) or trinitrophenol (TNP) with LPS as a mucosal adjuvant, in the presence or
absence of cholera toxin (CT). The antibody titers were measured in serum, saliva, and nasal wash
fluids by an enzyme-linked immunosorbent assay (ELISA) in IgM, IgG, and IgA isotype-specific
manner. The epitope-specific antibody production induced in blood and mucosal fluid was further
enhanced by LPS for all isotypes examined. Besides, LPS, which has rarely been regarded as a mucosal adjuvant, was tested for its adjuvanticity by comparing the nasal immunization with PC-KLH plus LPS or with PC-KLH plus CT. LPS showed high adjuvanticity almost equal to CT. Possible differences of LPS from CT as a mucosal adjuvant remains to be elucidated.

Full Text:

PDF

References

Ulevitch, R. J., and Tobias, P. S. (1995) Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol 13:437-457.

Gery, I., Kruger, J., and Spiesel, S. Z., (1972) Stimulation of B-lymphocytes by endotoxin. Reaction of Thymusdeprived mice and karyotypic analysis of dividing cells in mice bearing T6T6 thymus grafts. J. Immunol 108:1088.

Skidmore, B. J., Chiller,J. M., Morrison, D. C., and Weigle, W. O. (1975) Immunologic properties of bacterial lipopolysaccharide (LPS): correlation between the mitigenic, adjuvant, and immunogenic activities, J. Immunol 114:770-775.

Medzhitov, R., Preston-Hurlburt, P., and Janeway, C. A. Jr., (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity, Nature 388: 394-397.

Chow, J. C., Young, D. W., Golenbock, D.

T., Christ, W. J., and Gusovsky, F. (1999)

Toll-like receptor-4 mediates

lipopolysaccharide-induced signal

transduction. J. Biol. Chem. 274:1068910692.

Kawai, T., and Akira, S. (2007) TLR signaling. Semin. Immunol 19:24-32.

McAleer, J. P., and Vella, A. T. (2008) Understanding how lipopolysaccharide impact CD4 T-cell immunity. Crit. Rev. Immunol 28:281-199.

Ishii, K. J., and Akira, S. (2007) Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol 27: 363-371.

Ulevitch, R. J., and Tobias, P. S. (1999) Recognation of Gram-negative and endotoxin by the innate immune system. Curr. Opin. Immunol 11:19-22.

Schijns, V. E. (2000) Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol 12:456-463.

McGhee, J. R., and Fujihashi, K. (2012) Inside the mucosal immune system. PloS Biol. 10(9): e1001397.

Eriksson, K., and Holmgren, J. (2002) Recent advances in mucosal vaccines and adjuvants. Curr. Opin. Immunol 14:666-672

Xu-Amano, J., Jackson, R. J., Fujihashi, K., Kiyono, H., Staats, H. S., and McGhee, J.R. (1994) Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine 12:903-911.

Vadolas, J., Davies, J. K., Wrigth, P. J., and Stugnell, R. A. (1995) Intranasal immunization with liposomes induces strong mucosal immune response in mice. Eur. J. Immunol. 25:969-975.

Vajdy, M., Kosco-Vilbois, M. H., Kopf, M., Kohler, G., and Lycke, N. (1995) Impaired Mucosal immune responses in interleukin 4-targeted mice. J. Exp. Med.181:41-53.

Harnett, W. and Harnett M. M. (1999) Phosphorylcholine: friend or foe of the immune system? Immunol Today 20:125-129.

Fischer, W., Behr, T., Hartmann, R., Peter-Katalini, J., and Egge, H. (1993) Teichoic acid and lipoteichoic acid of Streptococcus pneumoniae possess identical chain structures. A

reinvestigation of teichoic acid (C polysaccharide). Eur. J. Biochem. 215:851-857.

Wallick, S., Claflin, J. L., and Briles, D. E. (1983) Resistance to Streptococcus pneumoniae is induced by a Phosphorylcholine-protein conjugate. J. Immunol. 130:2871-1875.

Baatarjav, T., Kataoka, K., Gilbert, R. S., Terao, Y., Fukui, M., Goto, M., Kawabata, S., Yamamoto, M., Fujihashi, K., and Ito, H-O (2011) Mucosal immune features to phosphorylcholine by nasal Flt3 ligand cDNA-based vaccination. doi:10.1016/j.vaccine.2011.05.097

Cerny, J., Wallich, R., and Hammerling, J. (1982) Analysis of T15 idiotopes by monoclonal antibodies: variability of idiotopic expression on phosphorylcholine-specific lymphocytes from individual inbred mice. J. Immunol. 128:1885-1891.

Perlmutter, R. M., Crews, S. T., Douglas, R., Sorensen, G., Johnson, N., Nivera, N., Gearhart, P. J., and Hood, L. (1984) The generation of diversity in phosphorylcholine binding antibodies.

Adv. Immunol 35:1-37.

Briles, D. E., Forman, C., Hudak, S., and Claflin, J. L. (1982) Antiphosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J. Exp. Med. 156:1177-1185.

Masmoudi, H., Mota-Santos, T., Huetz, F., Coutinho, A., and Cazenave, P. A. (1990) All T15 Id-positive antibodies (but not the majority of VHT15+antibodies) are produced by peritoneal

CD5+ B lymphocytes. Int Immunol. 2:515-520.

Macpherson, A. J., Gatto, D., Sainsbury, E., Harriman, G. R., Hengartner, H., and Zinkernagel, R. M. (2000) A primitive T cell-independent mechanism of intestinal mucosal IgA responses to

commensal bacteria. Science 288:2222-2226.

Kataoka, K., Fujihashi, K., Sekine, S., Fukuiwa, T., Kobayashi, R., Suzuki, H., Nagata, H., Takatsu, K., Shizukuishi, S., McGhee, J. R., and Fujihashi, K. (2007) Nasal cholera toxin elicits IL-5 and IL-5 receptor alpha-chain expressing B-1a B cells for innate mucosal IgA antibody responses. J Immunol 178:6058-6065.

Tanaka, N., Fukuyama, S., Fukuiwa, T., Kawabata, M., Sagara, Y., Ito, H-O, Miwa, Y., Nagatake, T., Kiyono, H., and Kurono, Y. (2007) Intranasal immunization with phosphorylcholine induces antigen specific mucosal and systemic immune responses in mice. Vaccine 25:2680-2687.

Johnson, A. G., Gaines, S., and Landy, M. (1956) Study on the O antigen of Salmonella Typhosa. V. Enhanchment of antibody response to protein antigens by the purified lipopolysaccharide. 103:225-246.

Hoebe, K., Janssen, M. E., Kim, S. O., Alexopoulou, L., Flavell, R. A., Han, J., and Buetler, B. (2003) Upregulation of costimulatory molecules induced by lipopolysaccharide and doublestranded RNA occurs by Trifdependent and Trif-independentpathway. Nat. Immunol 4:1223-1229.

Tokoyoda, K., Zehentmeier, S., Negazy, A. N., Albrecht, I., Grun, J. R., Lohning, M., and Radbruch, A. (2009) Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. Immunity 30:721-730.

Briles, D. E., Nahm, M., Schroer, K., Davie, J., Baker, P., Kearney, J., and Barletta, R. (1981) Antiphosphorylcholine

antibodies found in normal mouse serum are protective

against intravenous infection with type 3 Streptococcus pneumoniae. J. Exp.Med. 153:694-705.

DOI: https://doi.org/10.22146/theindjdentres.65711